본문으로 건너뛰기
← 뒤로

From MAiD Referral to Targeted Therapy Success: A Case of -Mutated Anaplastic Thyroid Cancer.

증례보고 1/5 보강
Reports (MDPI) 📖 저널 OA 100% 2023: 1/1 OA 2024: 1/1 OA 2025: 13/13 OA 2026: 14/14 OA 2023~2026 2025 Vol.9(1)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: limited treatment options and prompting her to pursue medical assistance in dying (MAiD)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The complexities of accessing newer therapies in Canada's single-payer healthcare system are also emphasized. The utilization of newer rapid diagnostic technologies can have a direct impact on directing treatment for ATC and other aggressive malignancies.

Stubbert B, Stewart P, Winquist E, Cecchini M, Browne C

📝 환자 설명용 한 줄

: Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with a poor prognosis, where median survival typically ranges from 4 to 10 months.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Stubbert B, Stewart P, et al. (2025). From MAiD Referral to Targeted Therapy Success: A Case of -Mutated Anaplastic Thyroid Cancer.. Reports (MDPI), 9(1). https://doi.org/10.3390/reports9010010
MLA Stubbert B, et al.. "From MAiD Referral to Targeted Therapy Success: A Case of -Mutated Anaplastic Thyroid Cancer.." Reports (MDPI), vol. 9, no. 1, 2025.
PMID 41562808 ↗

Abstract

: Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with a poor prognosis, where median survival typically ranges from 4 to 10 months. Advances in genetic profiling, particularly the identification of mutations, offer new opportunities for targeted therapy. : This case report details the journey of a woman in her late 50s diagnosed with symptomatic ATC. Initial immunohistochemistry (IHC) testing for mutations returned negative results, leaving the patient with limited treatment options and prompting her to pursue medical assistance in dying (MAiD). However, next-generation sequencing (NGS) confirmed a mutation, and a basis for targeted therapy. The patient began treatment with dabrafenib-trametinib, followed by pembrolizumab as second-line therapy, ultimately extending her life by nearly seven months. : This case underscores the importance of rapid and comprehensive diagnostic approaches, particularly the higher sensitivity of NGS over IHC for detecting mutations. The complexities of accessing newer therapies in Canada's single-payer healthcare system are also emphasized. The utilization of newer rapid diagnostic technologies can have a direct impact on directing treatment for ATC and other aggressive malignancies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기